Tumour Debulking and Reduction in Predicted Risk of Tumour Lysis Syndrome With Single-Agent Ibrutinib in Patients With Chronic Lymphocytic Leukaemia
British Journal of Haematology - United Kingdom
doi 10.1111/bjh.15791
Full Text
Open PDFAbstract
Available in full text
Categories
Date
February 10, 2019
Authors
Publisher
Wiley